The exon-intron organisation of the PBRM1 gene. Exons are shown as dark blue boxes and broken lines connecting the exons indicate introns. Exon and intron sizes are in scale.
Schematic diagram of the PBRM1 (BAF180) protein. : bromodomain 1-6; BAH1 and BAH2: bromo-adjacent homology domains 1 and 2; HMG: high mobility group domain.
Expression
PBRM1 is ubiquitously expressed during mouse embryonic development (Wang et al., 2004) , and has been detected in various human tissues including pancreas, kidney, skeletal muscle, liver, lung, placenta, brain, heart, intestine, ovaries, testis, prostate, thymus and spleen (Xue et al., 2000; Horikawa and Barrett, 2002) .
Localisation
PBRM1 protein localises to the nucleus of cells (Nicolas and Goodwin, 1996) . As a component of the PBAF chromatin-remodelling complex, it associates with chromatin (Thompson, 2009) , and has been reported to confer the localisation of PBAF complex to the kinetochores of mitotic chromosomes (Xue et al., 2000) .
Function
PBRM1/BAF180 functions in the regulation of gene expression as a constituent of the evolutionaryconserved SWI/SNF chromatin remodelling complexes (Euskirchen et al., 2012) . Beside BRD7 and BAF200, PBRM1 is one of the unique components of the SWI/SNF-B complex also known as polybromo/BRG1-associated factors (or PBAF), absent in the SWI/SNF-A (BAF) complex (Xue et al., 2000; Brownlee et al., 2012) . On that account, and because it contains bromodomains known to mediate binding to acetylated histones, PBRM1 has been postulated to target PBAF complex to specific chromatin sites, therefore providing the functional selectivity for the complex (Xue et al., 2000; Lemon et al., 2001; Brownlee et al., 2012) . Although direct evidence for PBRM1 involvement is lacking, SWI/SNF complexes have also been shown to play a role in DNA damage response (Park et al., 2006) . In vivo studies have shown that PBRM1 deletion leads to embryonic lethality in mice, where PBRM1 is required for mammalian cardiac chamber maturation and coronary vessel formation (Wang et al., 2004; Huang et al., 2008) . More recently, PBRM1 has acceded the continuously growing group of SWI/SNF subunits frequently mutated in cancer (Wilson and Roberts, 2011; Shain and Pollack, 2013) . PBRM1 mutations are most predominant in renal cell carcinomas detected in over 40% of cases, placing PBRM1 second (after VHL) on the list of most frequently mutated genes in this cancer (Varela et al., 2011; Hakimi et al., 2013; Peña-Llopis et al., 2012; . PBRM1 mutations have also been found in a smaller group of breast and pancreatic cancers (Xia et al., 2008; Shain et al., 2012; Numata et al., 2013) . Therefore, PBRM1 is considered a novel tumour suppressor in these cancers.
Homology
PBRM1 protein is highly conserved across animal kingdom, from flies and worms though all vertebrates to humans.
Mutations

Germinal
Germinal mutations of PBRM1 have not been reported.
Somatic
PBRM1 mutations have been found in a large fraction of clear cell renal cell carcinomas (Varela et al., 2011; Duns et al., 2012; Hakimi et al., 2013) , and to a smaller extend also in breast (Xia et al., 2008; Shain and Pollack, 2013) and pancreatic cancers (Numata et al., 2013; Shain and Pollack, 2013) . The vast majority of PBRM1 mutations found in renal and breast cancers are truncating (nonsense, frameshift insertions and deletions) (Varela et al., 2011; Hakimi et al., 2013) .
Implicated in
Renal cell carcinoma (RCC)
Note PBRM1 mutations and/or loss of protein expression have been reported in a large portion of clear cell subtype of RCC (Varela et al., 2011; Duns et al., 2012; Hakimi et al., 2013; Peña-Llopis et al., 2012; . Therefore, PBRM1 has been postulated to function as a tumour suppressor and the second major RCC cancer gene after VHL. PBRM1 mutations are largely mutually exclusive with BAP1 mutations (Peña-Llopis et al., 2012; Kapur et al., 2013) . Prognosis PBRM1 mutations are more common in patients with advance stages (Hakimi et al., 2013) and loss of PBRM1 protein expression has been associated with advanced tumour stage, low differentiation grade and worse patient outcome . In another study, no correlation between PBRM1 status and tumour grade was found (Peña-Llopis et al., 2012) . Although PBRM1-mutant tumours are associated with better prognosis than BAP1-mutant tumours, tumours mutated for both PBRM1 and BAP1 exhibit the greatest aggressiveness (Kapur et al., 2013) .
Breast cancer
Note
Truncating mutations have been identified in a minority of breast cancers (Xia et al., 2008) . In their study, authors showed inhibition of cell proliferation upon PBRM1 re-introduction into a mutant cell line, thus providing direct evidence for tumour suppressing role of PBRM1 in breast cancer.
Pancreatic cancer
Note
Mutations in PBRM1 have been reported in a small fraction of pancreatic cancer samples (Numata et al., 2013) .
